Sundial Growers finalizes license agreement and share purchase transaction with Pathway Rx.

Date Closed

July 31, 2019

Lead Office


On July 5, 2019, Sundial Growers and Pathway Rx filed a share purchase agreement in which Sundial acquired 50% of the issued and outstanding shares of Pathway in consideration for an aggregate 296,800 common shares. This transaction is a central part of Sundial's strategy to enter the Canadian medical cannabis business and provide medical cannabis products targeted for use with specific medical conditions.

Sundial Growers is a licensed cannabis producer based in Alberta which provides recreational and medical cannabis products.

McCarthy Tétrault advised Sundial with a team led by Greg Turnbull that included Nathan Robb, Curtis Merry, Simran Choongh (Business) and Vincent Yip (Intellectual Property).